Indications for: MULPLETA
Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Start treatment 8–14 days prior to a procedure. Should undergo procedure within 2–8 days after last dose. Take with or without food. 3mg once daily for 7 days.
Obtain platelet count prior to treatment and not more than 2 days prior to procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Ongoing or prior thrombosis or absence of hepatopetal blood flow: use only if potential benefit justifies risk. Do not use to normalize platelet counts. Pregnancy: may cause fetal harm. Nursing mothers: not recommended (during and for ≥28 days after last dose).
Thrombopoietin receptor agonist.
Headache; portal vein thrombosis.
Generic Drug Availability: